<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449019</url>
  </required_header>
  <id_info>
    <org_study_id>DPI</org_study_id>
    <nct_id>NCT01449019</nct_id>
  </id_info>
  <brief_title>The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <acronym>DFG_5</acronym>
  <official_title>The Contribution of Glucagon-like Peptide 1 (GLP-1) to the Entero-insulinar Axis in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide
      1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in
      healthy subjects and patients with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incretin effect</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The incretin effect is the difference between postprandial plasma concentrations of insulin and C-peptide, respectively, and those during the isoglycemic fasting control experiment. The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of glucagon</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of insulin</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of C-peptide</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Glucagon-like peptide-1(7-36) (GLP-1(7-36))</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP)</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>intravenous infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intraduodenal perfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin(9-39)amide</intervention_name>
    <description>intravenous infusion of exendin(9-39)</description>
    <arm_group_label>intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>intravenous infusion of saline</description>
    <arm_group_label>intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>duodenal meal</intervention_name>
    <description>duodenal perfusion of a meal</description>
    <arm_group_label>intraduodenal perfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>duodenal saline</intervention_name>
    <description>duodenal perfusion of saline</description>
    <arm_group_label>intraduodenal perfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female (postmenopausal, surgically sterile or using double-barrier method of
             contraception) healthy subjects and patients with type 2 diabetes mellitus (T2DM)

          -  must be able to complete a 1 week wash-out of current anti-diabetic medications

          -  Age 30-70 years

          -  HbA1c (Hemoglobin A1c) ≤11% at screening

          -  Body mass index (BMI) &lt;40 kg/m2

          -  Patients with type 2 diabetes mellitus (T2DM): Must have a fasting blood glucose of
             ≤12.2 mmol/L (240 mg/dL) at screening

          -  Able to provide written informed consent prior to study participation

          -  Able to communicate well with the investigator and comply with the requirements of the
             study

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus (T1DM), diabetes as a result of pancreatic
             injury, or secondary forms of diabetes (eg Cushing, acromegaly)

          -  Need for insulin within the previous 3 months

          -  Use of Thiazolidinediones in the previous 4 weeks

          -  Significant concomitant disease or complications of diabetes (i.e. nephropathy,
             autonomic dysfunction, orthostasis).

          -  Treatment with systemic steroids and thyroid hormone (unstable dosage).

          -  Patients with any history of gastrointestinal surgery, e.g. partial bowel resections,
             partial gastric resections, etc.

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulation.

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.

          -  Significant illness within the two weeks prior to dosing.

          -  Past medical history of clinically significant ECG abnormalities or a family history
             of a prolonged QT-interval syndrome.

          -  History of clinically significant drug allergy; history of atopic allergy (asthma,
             urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs
             similar to the study drug.

          -  history of major gastrointestinal tract surgery such as gastrectomy,
             gastroenterostomy, or bowel resection;

          -  history or clinical evidence of pancreatic injury or pancreatitis;

          -  history or presence of impaired renal function as indicated by abnormal creatinine or
             urea val-ues or abnormal urinary constituents (e.g., albuminuria);

          -  evidence of urinary obstruction or difficulty in voiding at screening;

          -  Polymorphonuclears &lt;1500/µL at inclusion or platelet count &lt; 100,000/μL at screening
             and baseline.

          -  History of immunocompromise.

          -  Evidence of liver disease as indicated by abnormal transaminases and alkaline
             phosphatase exceeding twice the upper limit of the normal range, and serum bilirubin
             should not exceed the value of 27 µmol/L (1.6 mg/dL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Schirra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Unit (CRU), Department of Internal Medicine, Campus Großhadern, Clinical Center of Ludwig-Maximilians-University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Maximilians-University, Clinical Research Unit</name>
      <address>
        <city>Munich</city>
        <zip>80999</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Joerg Schirra</investigator_full_name>
    <investigator_title>Principal investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Exendin(9-39)</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glucagon</keyword>
  <keyword>T2DM</keyword>
  <keyword>incretin effect</keyword>
  <keyword>human physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

